NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB:PRTX) announced today that Joe J. Dervan, Ph.D., Director of Protein Chemistry and Biopharmaceutical Manufacturing at Protalex, will present pre-clinical efficacy data from the collagen induced arthritis study of the Company’s PRTX-100 compound in development for the treatment of autoimmune and inflammatory diseases, at the Fifth International Conference on Autoimmunity, taking place November 29- December 3, 2006, at the Hilton Sorrento Palace Hotel, in Sorrento, Italy.
